Tuesday, 6 December 2022, Zoom Webinar

zoom webinar

Date: Thursday, 6 December 2022
Time:  3-5 PM CET
Place: Zoom Webinar
 

Discussion topic:
One health: does it work? The example of Monkeypox
 

Chair: 

Joris Vandeputte, International Alliance for Biological Standardization
Kamel Senouci, ADVAC

Presentations :


Introduction by Joris Vandeputte
Update on the animal monkeypox:  Yoshi Nakazawa, US Centers for Disease Control and Prevention
Update on the human monkeypox:   Brett W. Petersen, US Centers for Disease Control and Prevention

Panel discussion:


Joris Vandeputte
Jean-Marie Okwo-Bele
Brett W. Petersen
Yoshi Nakazawa

Documents and links:
 
 

Thursday, 20 October 2022, Zoom Webinar

zoom webinar

Date: Thursday, 20 October 2022
Time:  18h30 to 20h30 EST
Place: Hotel Renaissance, Washington DC and Zoom access

   PLAY WEBINAR

 

Discussion topic:
Industry and vaccine development – dispelling some myths
 

Chair: 

Cristina Cassetti,
Division of Microbiology and Infectious Diseases, National Institutes of Allergy and   Infectious Diseases, US National Institutes of Health and long standing ADVAC Faculty

Presentations :


Penny Heaton
, J&J and Brad Gessner, Pfizer

Panel discussion:


Industry: Penny Heaton, J&J and Brad Gessner, Pfizer
Government: Hilary Marston, FDA
Academia: Kathy Neuzil, University of Maryland and Angela Branche, University of Rochester

Documents and links:
pdfIndustry and Vaccine Development: Dispelling Some Myths

Penny Heaton, M.D.

pdfScience and Public Health in the Pharma World

Brad Gessner

Tuesday, 13 September 2022, Zoom Webinar

zoom webinar

Date: Tuesday, 13 September 2022
Time:  15h00 to 17h00 CET
Place: ZOOM WEBINAR

   PLAY WEBINAR

 

Discussion topic:
The power and limitations of immunobridging studies: the example of COVID-19 vaccines
 
Chair: Hanna Nohynek,
Finnish Institute for Health and Welfare, Finland and Member of the ADVAC Scientific Committee
Presentations :

Bridging studies – why and how?
Peter Dull, Bill & Melinda Gates Foundation

Criteria and requirement for the licensing of new vaccines with special emphasis on COVID-19
the view of EMA. Marco Cavaleri, Head of Office Biological Health Threats and Vaccine Strategy, European Medicines Agency.

Panel discussion:  Strategies behind the variant adapted COVID-19 vaccines development
with participation from regulators, Godwin Enwere, WHO Prequalification Unit, Vikram Paradkar, Executive Vice-President   Production, Biological E, representing DCVMN, Jeff Roberts, Associate Vice-President Clinical Research, MSD, representing   IFPMA, and other experts.

Documents and links:

pdfVaccine development and immunobridging
what is it, why we do it….  And why it makes us nervous

Peter Dull

pdfCriteria and requirement for the licensing of new vaccines with special emphasis on COVID-19
the view of EMA

Marco Cavaleri


Thursday, 19 April 2022, Zoom Webinar

zoom webinar

Date: Thursday, 19 April 2022
Time:  15h00 to 17h00 (Geneva/Paris time)
Place: ZOOM WEBINAR

   PLAY WEBINAR

 

Discussion topic:
HPV vaccination: Prospect of moving to a one and only dose schedule
 
HPV Vaccination: The evidence in favour of a one and only dose schedule and its limitations
Presenter: Margaret Stanley, University of Cambridge, UK
Chair : Philippe Duclos, Director of ADVAC, University of Geneva
Documents and links:
 pdfHPV Vaccination:Prospect of moving to a one and only dose schedule

Presenter: Margaret Stanley, University of Cambridge, UK

Wednesday, 8 December 2021, Zoom Webinar

zoom webinar

Date: Wednesday, 8 December 2021
Time:  15h00 to 17h00 (Geneva/Paris time)
Place: ZOOM WEBINAR

   PLAY WEBINAR

 

Discussion topic:
Safety of COVID-19 Vaccines
 

COVID-19 Vaccine Safety – Perspective from WHO’s Global Advisory Committee on Vaccine Safety
Presenter: Rita Helfand, Chair, Global Advisory Committee on Vaccine Safety, WHO, and Senior Advisor for Science, National Center for Emerging and Zoonotic Infectious Diseases, CDC

COVID-19 Vaccine Safety – US experience
Presenter: Tom Shimabukuro, Acting Director, Immunization Safety Office, National Center for Emerging and Zoonotic Infectious Diseases, CDC

Chair: Melinda Wharton, Associate Director for Vaccine Policy, National Center for Immunization and Respiratory Diseases, US Centers for Disease Control and Prevention (CDC) and Member of the ADVAC Scientific Committee
Documents and links:
pdfPerspective from WHO’s Global Advisory Committee on Vaccine Safety
Presenter: Rita Helfand, Chair, Global Advisory Committee on Vaccine Safety, WHO, and Senior Advisor for Science, National Center for Emerging and Zoonotic Infectious Diseases, CDC
pdfCOVID-19 Vaccine Safety – US experience
Presenter: Tom Shimabukuro, Acting Director, Immunization Safety Office, National Center for Emerging and Zoonotic Infectious Diseases, CDC
 

html COVID-19 Vaccination and Non–COVID-19 Mortality Risk

Xu S, Huang R, Sy LS, et al. COVID-19 Vaccination and Non–COVID-19 Mortality Risk — Seven Integrated Health Care Organizations, United States, December 14, 2020–July 31, 2021. MMWR Morb Mortal Wkly Rep 2021;70:1520–1524.

Thursday, 4 November 2021, Zoom Webinar

zoom webinar

Date: Thursday, 4 November 2021
Time:  15h00 to 17h00 (Geneva/Paris time)
Place: ZOOM WEBINAR

   PLAY WEBINAR

 

Discussion topic:
Will the success of mRNA vaccine development platforms for COVID-19 lead to new platforms for old vaccines?
There will be two main presentations as follows:

The Immunological benefits of mRNA and potential applications
Presenter:  Barney Graham, previously with the National Institute of Health, USA

Regulatory approaches:  Issues and challenges, and questions to be asked by regulators
Presenter:  Philip Krause, Food & Drug Administration, USA

Dr Martin Friede, WHO will chair the meeting.

Documents and links:
pdfThe Immunological benefits of mRNA and potential applications
Presenter: Barney Graham, former Deputy Director of the NIAID Vaccine ResearchCenter, National Institute of Health, USA
pdfRegulatory approaches: Issues and challenges, and questions to be asked by regulators
Presenter: Philip Krause, Deputy Director of the Office of Vaccines Research and Review, Food & Drug
Administration, USA

Tuesday, 28 Sept 2021, Zoom Webinar Session 4

zoom webinar

Date: Tuesday, 28 September 2021
Time:  18h00 to 20h00 (Geneva time)
Place: ZOOM WEBINAR

   PLAY WEBINAR

 

Discussion topic:
Vacunas contra el COVID: ¿Hay necesidad de refuerzos en vista de la aparición de nuevas variantes y la disminución de la inmunidad?
Session 4 (en español)

Disertantes:
Professor Cristiana Toscano, Federal University of Goiás, Brazil
Evidencia para orientar la decisión sobre los esquemas de refuerzos de la vacunación contra COVID-19 ¿Qué sabemos y qué no sabemos?

Professor Celia Alpuche, Instituto Nacional de Salud Publica, Mexico
Desafíos y complejidades en el proceso de toma de decisiones para la vacunación COVID-19: experiencia de América Latina

Discusion:
Professor Alejandro Cravioto, Universidad Nacional Autónoma de México y Presidente del SAGE

Documents and links:
pdfEvidencia para orientar la decisión sobre los esquemas de refuerzos de la vacunación contra COVID-19 ¿Qué sabemos y qué no sabemos?
By Professor Cristiana Toscano, Federal University of Goiás, Brazil
pdfDesafíos y complejidades en el proceso de toma de decisiones para la vacunación COVID-19: experiencia de América Latina
By Professor Celia Alpuche, Instituto Nacional de Salud Publica, Mexico

Tuesday, 28 Sept 2021, Zoom Webinar Session 3

zoom webinar

Date: Tuesday, 28 September 2021
Time:  17h00 to 19h00 (Geneva time)
Place: ZOOM WEBINAR

   PLAY WEBINAR

 

Discussion topic:
COVID vaccines – is there a need for boosters in view of the emergence of variants and waning immunity?
Session 3 (in english)
Presenters:
Dr Jakob Cramer, Coalition for Epidemic Preparedness Innovations (CEPI), London, UK
Booster versus 2+1 primary immunisation vaccination: Does it matter?
Professor Stanley Plotkin, University of Pennsylvania, USA
Correlates of Protection as Indicators for Third Doses of COVID Vaccines
Documents and links:

pdfBooster vaccination versus 2+1 primary immunization: Does it matter?
By Dr Jakob Cramer, Coalition for Epidemic Preparedness Innovations (CEPI), London, UK

pdfCorrelates of Protection as Indicators for Third Doses of COVID Vaccines
By Professor Stanley A. Plotkin | University of Pennsylvania, USA

Tuesday, 28 Sept 2021, Zoom Webinar Session 2

zoom webinar

Date: Tuesday, 28 September 2021
Time:  14h00 to 16h00 (Geneva time)
Place: ZOOM WEBINAR

   PLAY WEBINAR

 

Discussion topic:
Vaccins COVID - est-il nécessaire de procéder à des rappels compte tenu de l'émergence de variants et de la baisse de l'immunité dans le temps?
Session 2 (en français)

Orateurs:
Dre Christiane Eberhardt et Prof. Arnaud Didierlaurent, Université de Genève
Pour quoi, pour qui et pour quand? La 3ème dose du vaccin COVID-19 en question !

Documents and links:

pdfPour quoi, pour qui et pour quand? La 3ème dose du vaccin COVID-19 en question !
By Dre Christiane Eberhardt and Prof. Arnaud Didierlaurent, Centre de Vaccinologie, Genève



Tuesday, 28 Sept 2021, Zoom Webinar Session 1

zoom webinar

Date: Tuesday, 28 September 2021
Time:  10h00 to 12h00 (Geneva time)
Place: ZOOM WEBINAR

   PLAY WEBINAR

 

Discussion topic:
COVID vaccines – is there a need for boosters in view of the emergence of variants and waning immunity?
Session 1 (in english)
Presenters:
Dr Jakob Cramer, Coalition for Epidemic Preparedness Innovations (CEPI), London, UK
Booster versus 2+1 primary immunisation vaccination: Does it matter?
Dr Jerome Kim, International Vaccine Institute, Seoul, Republic of Korea
The booster in your future: when, what, and why?
Documents and links:

pdfBooster vaccination versus 2+1 primary immunization: Does it matter?
By Dr Jakob Cramer, Coalition for Epidemic Preparedness Innovations (CEPI), London, UK

pdfThe booster in your future: when, what, and why?
By Dr Jerome H. Kim, MD | International Vaccine Institute



Tuesday, 8 June 2021, Zoom Webinar

zoom webinar

Date: Tuesday, 8 June 2021
Time:  14h00 to 16h00 (Geneva time)
Place: ZOOM WEBINAR

   PLAY WEBINAR

 

Discussion topic:
The impact of COVID-19 on the immunization programmes and how to correct the situation.
Presenters:

Dr Richard Mihigo, WHO Regional Office for Africa
Dr Magdalena Bastias, Immunization Department, Ministry of Health, Chile and member of the Global NITAG Network Steering Committee

Documents and links:
pdfImpact of Covid-19 in Immunization in the African Region
VPD, WHO AFRO | By Dr. Richard Mihigo

pdfThe impact of COVID-19 on the immunisation programmes : Country perspective: Chile
By Magdalena Bastías



Thursday, 1 April 2021, Webinar

webinar 9 December 2020

Date: Thursday, 1 April 2021
Time:  14h00 to 16h00 (Geneva time)
Place: ZOOM WEBINAR

   PLAY WEBINAR

 

Discussion topic:
Logistics of deployment of COVID vaccines on a global level  - how vaccines will make it to the most vulnerable populations 
Presenters:
Professor Lisa Cooper, Johns Hopkins Bloomberg School of Public Health
Dr Katherine O’Brien, WHO
Chairs:
Professor Anna Durbin, John Hopkins Bloomberg School of Public Health
Dr Emily Erbelding, NIAID/National Institutes of Health, USA.
Documents and links:
pdfVaccine Equity among At-Risk Populations in the United States
by Lisa A. Cooper, MD MPH

pdfDeployment of COVID vaccines globally to those most in needOne year on in the life of Covid-19 pandemic
By Kate O’Brien, IVB Director



Wednesday, 9 December 2020, Webinar

webinar 9 December 2020

Date: 9 December 2020
Time:  13h00 to 15h00 (Geneva time)
Place: WEBINAR

   PLAY WEBINAR

 

Discussion topic:
Contextualization of the results of COVID vaccine trials: implications for national decision-making, future and ongoing trials, and post-licensure surveillance
Presenter:  Professor Peter Smith, London School of Hygiene and Tropical Medicine, UK
Title of presentation:  Early results from COVID-19 vaccine trials and implications for ongoing and future trials of other COVID-19 vaccines
Presenter:  Professor Nick Andrews, Public Health England, UK
Title of presentation:  Approaches to study vaccine impact post-licensure, both vaccine effectiveness and safety
Documents and links:
pdfEarly results from COVID-19 vaccine trials and implications for ongoing and future trials of other COVID-19 vaccines (pdf file)
Presentation of Peter Smith
pdfApproaches to study vaccine impact post-licensure, both vaccine effectiveness and safety (pdf file)
Presentation of Nick Andrews

Tuesday, 26 May 2020, Webinar

webinar 2020 05 26

Date: 26 May 2020
Time:  16h00 (Geneva time)
Place: WEBINAR

  Play Webinar

 

Discussion topic:
Polio Eradication Endgame: a novel oral polio vaccine on the horizon
Presenter:  Dr Ananda Bandyopadhyay, Bill & Melinda Gates Foundation
Documents and links:
pdfPresentation of Ananda S. Bandyopadhyay:
Polio Eradication Endgame: A Novel Oral Polio Vaccine On The Horizon.
 
(pdf file)
pptPresentation of Ananda S. Bandyopadhyay:
Polio Eradication Endgame: A Novel Oral Polio Vaccine On The Horizon.
(pptx file)

Tuesday, 25 February 2020, during NITAG (CDC, Atlanta)

NITAG Atlanta

Date: 25 February 2020
Time:  18h00 (6pm)
Place: Emory University, School of Medicine Building
 

Discussion topic:

AEFI compensation programs - as in country preparedness, feasibility, resource availability (legal, economic) and communications

Presenter:  Dr Eve Dubé, National Institute of Public Health of Quebec, Canada

Documents and links:
pdfPresentation of Dr Eve Dubé: AEFI compensation programs. (pdf file)

Tuesday, 8 October 2019, during SAGE (WHO Geneva)

WHO Geneva

Date: 8 October 2019
Time:  Lunch-time meeting
Place: WHO Library meeting room
 

Discussion topic:

Topic:  The second valley of death

Presenter:  Dr David Kaslow, PATH

Documents and links:
pdfPresentation of David Kaslow: The second valley of death. (pdf file)

Thursday, 3 October 2019, during IDSA, Washington D.C.

IDSA Washington

Date: 3 October 2019
Time:  Evening meeting -18h30
Place: Renaissance Washington DC Downtown Hotel,
999 9th St NW, Washington, DC
 

Discussion topic:

Vaccine hesitancy

1st presentation: A scientific response to a traumatic experience
Presenter: Professor Stanley Plotkin, University of Pennsylvania

2nd presentation: Vaccine confidence in the era of viral misinformation
Presenter: Dr Theresa Tam, Chief Public Health Officer, Public Health Agency of Canada

Documents and links:
pdfPresentation of Stanley Plotkin: A scientific response to a traumatic expereience. (pdf file)
pdfPresentation of Theresa Tam: Vaccine confidence in the era of viral misinformation. (pdf file)

Tuesday, 7 May 2019, during the meeting of ESPID, Ljubljana, Slovenia

ESPID Ljubljana

Date: 7 May 2019
Time:  Evening meeting (20 hrs.)
Place: Kocka Hall, ESPID Convention Centre
 

Discussion topic:

Novel approaches to the prevention of RSV

Presenters:  Dr Flor M. Munoz, Baylor College of Medicine and Dr Octavio Ramilo, Nationwide Children's Hospital 

Documents and links:
pdfNovel approaches for prevention of RSV infection: New anti-RSV monoclonal antibodies (pdf file)
pdfOption for RSV prevention maternal immunization (pdf file)

Tuesday, 2 April 2019, during the meeting of SAGE, Geneva

WHO Geneva

Date: 2 April 2019
Time:  Lunch-time
Place: Room 18, International Conference Centre Geneva (CICG), 17 rue de Varembé, 1211 Geneva 20
 

Discussion theme:
How can we make school immunization a positive experience?
Presenters:  Dr Noni MacDonald and Dr Nikki Turner

Documents and links:
pptPlace of school immunization & How can we make school immunization a positive (pptx file)
pdfPlace of school immunization & How can we make school immunization a positive (pdf file)

Tuesday, 23 October 2018 during the meeting of SAGE, Geneva

WHOGeneva

Date: Tuesday, 23 October 2018
Time:  Lunch-time (when the SAGE session breaks for lunch)
Place: Room 18, International Conference Centre Geneva (CICG), 17 rue de Varembé, 1211 Geneva 20
 

Discussion topic:
Is there a role for human challenge trials in the vaccine licensing process?
Dr Andy Pollard, University of Oxford will introduce and present the topic and Dr Ivana Knezevic, Norms and Standards for Biologicals, WHO will present the WHO perspective.

Food and drinks will be provided during the meeting.  

Please note that we are not able to cover travel or accommodation expenses of participants.

For organizational purposes, it would be appreciated if you could let us know if you plan to attend.  You can indicate your interest by sending an email to This email address is being protected from spambots. You need JavaScript enabled to view it.


Documents and links:
pdfAndrew J Pollard - Controlled human infection models (pdf file)
pptIvana Knezevic - WHO perspective on Human Challenge Trials in Vaccine Developpement and Licensing (pptx file)
pdfIvana Knezevic - WHO perspective on Human Challenge Trials in Vaccine Developpement and Licensing (pdf file)

Thursday, 4 October 2018 during IDSA Week, San Francisco, USA

IDSA SanFrancisco

Date: Thursday, 4 October 2018
Time:  Evening meeting - 18h30 to 21h30 
Place: Hotel Spero, Californian Room, 405 Taylor Street, San Francisco, CA94102. 
The hotel is centrally located around 15 mins. on foot from the Moscone Center where the IDSA Conference will be held, a 5-minute taxi ride from the Moscone Center or you can take the bus No. 38.
 

Discussion topic:
Pneumococcal vaccination of the older adult. 
The topic will be presented by Dr Cynthia Whitney, Senior Subject Matter Expert, IHRC Inc., Atlanta.   
Dr Edwin Asturias and Dr Keipp Talbot will co-chair the meeting and lead discussions.  

Food and drinks will be provided during the meeting.  

Please note that we are not able to cover travel or accommodation expenses of participants.

For organizational purposes, it would be appreciated if you could let us know if you plan to attend.  You can indicate your interest by sending an email to This email address is being protected from spambots. You need JavaScript enabled to view it.


Documents and links:
pdfCynthia Whitney presentation on Pneumococcal Vaccines (pdf file)
pptCynthia Whitney presentation on Pneumococcal Vaccines (pptx file)

Tuesday, 30 May 2018 during the meeting of ESPID, Malmoe

ESPID Malmoe

Date: Tuesday, 30 May 2018
Time:  Evening
Place:  
 

Discussion topic:
What can we learn from the recent Dengue vaccine issue?

Documents and links:
pdfAnnelies Wilder-Smith's presentation on Dengue Vaccine (pdf file)

Tuesday, 17 April 2018 during the meeting of SAGE, Geneva

WHO Geneva

Date: Tuesday, 23 October 2018
Time:  Lunch-time (when the SAGE session breaks for lunch)
Place: Room 18, International Conference Centre Geneva (CICG), 17 rue de Varembé, 1211 Geneva 20
 

Discussion topic:
Is there a future for mandatory vaccination?
Dr Andy Pollard, University of Oxford will introduce and present the topic and Dr Ivana Knezevic, Norms and Standards for Biologicals, WHO will present the WHO perspective.

Documents and links:
Noni MacDonald's Article on Mandatory infant & childhood immunizationon Mandatory infant & childhood immunization (web link)
pdfNoni's presentation (pdf file)